Back to News
Market Impact: 0.15
MRVI Crosses Above Average Analyst Target
Source: Nasdaq
Analyst EstimatesHealthcare & BiotechMarket Technicals & Flows
Maravai LifeSciences shares rose above the average 12-month analyst price target of $7.42, trading at $7.65 per share. The move places MRVI beyond consensus valuation expectations and could prompt analysts to reassess their targets, but the article provides no new fundamental or earnings information.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MRVI0.20
More News
- Bond market alarms are ringing on Wall Street. Here's what's ahead
- Warsh's regime change at the Fed pushes ahead – and meets resistance
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Oil Prices Decline on Hopes of a Hormuz Deal
- Bond Selloff Fades, US-Iran Said to be Exploring Phased Deal, Trump-Xi Summit
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors